作者: Michael A. WeberAjay J. KirtaneMatthew R. WeirJai RadhakrishnanTony DasMartin BerkFarrell MendelsohnAlain BouchardGerman LarrainMichael HaaseJuan Diaz-CartelleMartin B. Leon
作者单位: 1State University of New York, Downstate Medical Center, Brooklyn, New York
2Columbia University Medical Center/NewYork-Presbyterian Hospital, New York, New York
3Cardiovascular Research Foundation, New York, New York
4University of Maryland School of Medicine, Baltimore, Maryland
5Texas Health Presbyterian Hospital, Dallas, Texas
6Baptist Medical Center Princeton, Cardiology PC Research, Birmingham, Alabama
7Aspirus Heart and Vascular Institute, Wausau, Wisconsin
8Boston Scientific, Marlborough, Massachusetts
刊名: JACC: Cardiovascular Interventions, 2020, Vol.13 (4), pp.461-470
来源数据库: Elsevier Journal
DOI: 10.1016/j.jcin.2019.10.061
关键词: Antihypertensive agentsCatheter ablationHypertensionRenal artery
英文摘要: Abstract(#br)Objectives(#br)The aim of this study was to investigate bipolar radiofrequency renal denervation in patients with hypertension not receiving medications at baseline.(#br)Background(#br)A blood pressure–reducing effect of renal denervation has been difficult to isolate in clinical investigations.(#br)Methods(#br)REDUCE HTN: REINFORCE (Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension) was a randomized, sham-controlled multicenter trial. Patients with office systolic blood pressure (SBP) of 150 to 180 mm Hg and average 24-h ambulatory SBP of 135 to 170 mm Hg after medication washout underwent bipolar radiofrequency renal denervation or a sham procedure. The planned outcome was 8-week change in 24-h ambulatory SBP. Enrollment was...
全文获取路径: Elsevier  (合作)
影响因子:6.552 (2012)